[1]姜丽莉,王 静,李振凤,等.甲巯咪唑对初诊Graves’病患者血清相关细胞因子及microRNAs水平的影响[J].医学信息,2020,33(08):101-104.[doi:10.3969/j.issn.1006-1959.2020.08.031]
　JIANG Li-li,WANG Jing,LI Zhen-feng,et al.Effects of Methimazole on Serum Levels of Cytokines and microRNAs in Newly Diagnosed Graves’ Disease Patients[J].Medical Information,2020,33(08):101-104.[doi:10.3969/j.issn.1006-1959.2020.08.031]
点击复制

甲巯咪唑对初诊Graves’病患者血清相关细胞因子及microRNAs水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年08期
页码:
101-104
栏目:
论著
出版日期:
2020-04-15

文章信息/Info

Title:
Effects of Methimazole on Serum Levels of Cytokines and microRNAs in Newly Diagnosed Graves’ Disease Patients
文章编号:
1006-1959（2020）08-0101-04
作者:
姜丽莉; 王 静; 李振凤; 等
（1.青岛大学医学部基础医学院免疫学系，山东 青岛 266071；2.海阳市人民医院检验科，山东 海阳 265100；3.潍坊医学院医学研究实验中心，山东 潍坊 261053）
Author(s):
JIANG Li-li; WANG Jing; LI Zhen-feng; et al
(1.Department of Immunology,School of Basic Medical Sciences,Qingdao University,Qingdao 266071,Shandong,China;2.Department of Laboratory Medicine,Haiyang People’s Hospital,Haiyang 265100,Shandong,China;3.Medical Research Experimental Center of Weifang Medical College,Weifang 261053,Shandong,China)
关键词:
Graves’病; 甲巯咪唑; 细胞因子; microRNAs
Keywords:
Graves’ disease; Methimazole; Cytokines; microRNAs
分类号:
R511.5
DOI:
10.3969/j.issn.1006-1959.2020.08.031
文献标志码:
A
摘要:
目的 探讨甲巯咪唑对初诊Graves’病患者血清相关细胞因子及microRNAs（miRNAs）水平的影响。方法 选取2016年12月~2019年1月于海阳市人民医院内分泌科就诊的36例Graves’病初诊患者为疾病组，给予甲巯咪唑治疗。另选取同期30例健康志愿者作为健康对照组。比较疾病组治疗前、治疗后及健康对照组甲状腺功能指标[游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）、促甲状腺激素受体抗体（TRAb）]、细胞因子[IL-2、IL-6、IL-17、TGF-β1]、hs-CRP、microRNAs[miR-16、miR-142-3p、miR-146a、miR-155]的水平。结果 疾病组治疗前FT3、FT4，TRAb，IL-6、IL-17、TGF-β1、hs-CRP，miR-16、miR-142-3p、miR-155水平高于健康对照组，TSH、IL-2及miR-146a水平低于健康对照组，差异有统计学意义（P＜0.05）。疾病组治疗后FT3、FT4、TRAb、IL-6、TGF-β1、hs-CRP、miR-16、miR-142-3p、miR-155水平低于治疗前，而TSH、IL-2、miR-146a水平高于治疗前，差异有统计学意义（P＜0.05）；IL-17水平治疗前后比较，差异无统计学意义（P＞0.05）。疾病组治疗后TSH、IL-2、miR-146a水平低于健康对照组，IL-6、IL-17、TGF-β1、hs-CRP、miR-16、miR-155水平高于健康对照组，差异有统计学意义（P＜0.05），两组FT3、FT4、TRAb及miR-142-3p水平比较，差异无统计学意义表（P＞0.05）。结论 甲巯咪唑可改善Graves’病患者的甲状腺功能，血清相关细胞因子及miRNAs可作为该病临床诊疗的辅助指标。
Abstract:
Objective To investigate the effect of methimazole on serum-related cytokines and microRNAs(miRNAs) in newly diagnosed Graves’ disease patients.Methods From December 2016 to January 2019,36 newly diagnosed patients with Graves’ disease who were treated in the Department of Endocrinology of Haiyang People’s Hospital were selected as the disease group and treated with thiamazole.Another 30 healthy volunteers in the same period were selected as the healthy control group.Comparision of thyroid function indexes before treatment ,after treatment of disease group and healthy control group[free triiodothyronine(FT3), free thyroxine(FT4), thyroid stimulating hormone(TSH),thyrotropin receptor antibody (TRAb)],Cytokines [IL-2,IL-6,IL-17,TGF-β1],hs-CRP,microRNAs[miR-16,miR-142-3p,miR-146a,miR-155].Results Before treatment,the levels of FT3,FT4,TRAb,IL-6,IL-17,TGF-β1,hs-CRP,miR-16,miR-142-3p,and miR-155 were higher than those of healthy controls,TSH,IL- 2 and miR-146a levels were lower than the healthy control group,the difference was statistically significant(P<0.05).After treatment,the levels of FT3,FT4TRAb,IL-6, TGF-β1,hs-CRP,miR-16,miR-142-3p,and miR-155 were lower than before treatment,the levels of TSH,IL-2 and miR-146a were higher than before treatment,the difference was statistically significant(P<0.05); the IL-17 level before and after treatment had no significant difference(P>0.05). After treatment,the levels of TSH,IL-2,miR-146a in the disease group were lower than those in the healthy control group,IL-6,IL-17,TGF-β1,hs-CRP, miR-16,miR-155 were higher than the healthy control group,the difference was statistically significant(P<0.05). There was no statistically significant difference in FT3,FT4,TRAb and miR-142-3p levels between the two groups(P>0.05). Conclusion Thiamazole can improve thyroid function in patients with Graves’ disease.Serum-related cytokines and miRNAs can be used as auxiliary indicators for clinical diagnosis and treatment of this disease.

参考文献/References:

[1]Burch HB,Cooper DS.Management of Graves Disease:A Review[J].The Journal of the American Medical Association,2015,314(23):2544-2554.[2]Bartalena L.Diagnosis and management of Graves disease:a global overview[J].Nature Reviews Endocrinology,2013,9(12):724-734.[3]Naik V,Khadavi N,Naik MN,et al.Graves’ disease:clinical manifestations, immune pathogenesis (cytokines and chemokines)and therapy[J].Best Pract Res Clin Endocrinol Metab,2008,18(9):967-971.[4]Qin Q,Wang X,Yan N,et al.Aberrant expression of miRNA and mRNAs in lesioned tissues of Graves’disease[J].Cell Physiol Biochem,2015,35(5):1934-1942.[5]Merrill SJ,Minucci SB.Thyroid autoimmunity: an interplay of factors[M].Vitamins and hormones.Academic Press,2018(106):129-145.[6]操伟庆,季榕.白细胞介素17及其与多种疾病的关系[J].现代临床医学,2017,43(4):246-250.[7]Czarnywojtek A,Owecki M,Zgorzalewicz-Stachowiak M,et al.The Role of Serum C-Reactive Protein Measured by High-Sensitive Method in Thyroid Disease[J].Archivum Immunologiae Et Therapiae Experimentalis,2014,62(6):501-509.[8]Hiratsuka I,Yamada H,Munetsuna E,et al.Circulating microRNAs in Graves’ disease in relation to clinical activity[J].Thyroid,2016,26(10):1431-1440.[9]Yamada H,Itoh M,Hiratsuka I,et al.Circulating micro RNA s in autoimmune thyroid diseases[J].Clinical Endocrinology,2014,81(2):276-281.[10]Chen X,Huang F,Qi Y,et al.Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves’disease[J].Journal of Translational Medicine,2018,16(1)188.[11]Zheng L,Zhuang C,Wang X,et al.Serum miR‐146a,miR‐155,and miR‐210 as potential markers of Graves’disease[J].Jour

相似文献/References:

[1]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Medical Information,2018,31(08):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[2]蒋红梅.丙基硫氧嘧啶与甲巯咪唑治疗妊娠合并甲状腺功能亢进的疗效比较[J].医学信息,2019,32(05):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
　JIANG Hong-mei.Comparison of Propyl Thiouracil and Methimazole in the Treatment of Pregnancy with Hyperthyroidism[J].Medical Information,2019,32(08):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
[3]丹杨萍,谭丽艳,刘思聪,等.甲巯咪唑对Graves病患者血清FCRL3水平的影响[J].医学信息,2020,33(07):149.[doi:10.3969/j.issn.1006-1959.2020.07.048]
　DAN Yang-ping,TAN Li-yan,LIU Si-cong,et al.Effect of Methimazole on Serum FCRL3 Level in Patients with Graves Disease[J].Medical Information,2020,33(08):149.[doi:10.3969/j.issn.1006-1959.2020.07.048]
[4]徐晨曦.甲巯咪唑与丙硫氧嘧啶对甲亢患者甲状腺功能及肝功能指标的影响[J].医学信息,2022,35(08):147.[doi:10.3969/j.issn.1006-1959.2022.08.037]
　XU Chen-xi.Effect of Methimazole and Propylthiouracil on Thyroid Function and Liver Function in Patients with Hyperthyroidism[J].Medical Information,2022,35(08):147.[doi:10.3969/j.issn.1006-1959.2022.08.037]
[5]王跃慧,李春彦.匹伐他汀与阿托伐他汀对缺血性卒中患者疗效及安全性的对比研究[J].医学信息,2022,35(08):150.[doi:10.3969/j.issn.1006-1959.2022.08.038]
　WANG Yue-hui,LI Chun-yan.A comparative Study of the Efficacy and Safety of Pivastatin and Atorvastatin in Patients with Ischemic Stroke[J].Medical Information,2022,35(08):150.[doi:10.3969/j.issn.1006-1959.2022.08.038]

更新日期/Last Update: 2020-04-15